Bayer and Hologic Forge International Partnership to Expand Contrast-Enhanced Mammography Solutions

Sep 25, 2023 00:01 CST Updated 00:01

Hologic

Developer of Medical Imaging Systems and Diagnostic and Surgical Products

Bayer

Pharmaceutical Product R&D Developer

Source: Siyu MedTech

Reprint Requirements: Please indicate the source of the article at the beginning of the text, and you can reprint it directly.

On September 21, 2023, Hologic Inc. (NASDAQ: HOLX) and Bayer announced an international partnership to provideContrast-Enhanced Mammography (CEM)Solutions to Improve Breast Cancer Detection Levels for Women in Multiple Countries Across Europe, Canada, and the Asia-Pacific Region.

# About Breast Cancer andContrast-Enhanced Mammography (CEM)

According to data from the World Health Organization (WHO), in 2020, 2.3 million women worldwide were diagnosed with breast cancer, and 685,000 died. Treatment for breast cancer can be highly effective, especially when the disease is detected early.Early Stage。

CEM is an innovative breast imaging modality with high sensitivity and low cost, which combines digital mammography with the use of contrast agents to support breast cancer diagnosis and guide treatment decisions.

An increasing number of independent scientific publications confirm the value of CEM as an adjunct to mammography. It can be performed as part of routine clinical practice and used in various clinical settings, such as indeterminate results from prior imaging or preoperative assessment of disease extent.WhenMRIWhen unavailable or prohibited,It can also be a useful tool.

To promote this opportunity, Hologic and Bayer have launched an international partnership aimed at providing CEM to women in European, Canadian, and Asia-Pacific countries.This collaboration combines the leading technologies of both companies (Hologic 3D mammography system and Bayer CEM approved injection system), enabling the precise use of contrast agents during mammography examinations.。

▲Hologic 3Dimensions™ Breast Tomosynthesis System

In January 2023, Bayer announced that its iodine-based contrast agent Ultravist™-300, -370 has now been approved for use in the European Union.Contrast-Enhanced Mammography (CEM), this product can be used to evaluate and detect breast lesions, for X-ray techniques that require enhanced contrast, such as conventional radiography, angiography, and computed tomography. The product is available in over 100 countries and currently has more than 18 million uses per year.

The two companies said that in the future, they will provide practical training for clinicians to help them apply CEM more effectively into their workflows.In addition, CEM can be used as part of routine clinical practice to reevaluate uncertain findings from prior imaging studies or to assess the extent of breast cancer in patients preoperatively; furthermore,When magnetic resonance imaging (MRI) is unavailable or contraindicated, it can also serve as a useful alternative tool.

"In the past few years, we have seen an increasing interest in contrast-enhanced mammography as an additional diagnostic tool. Our collaboration with Bayer will enable clinicians around the world to incorporate CEM into the breast cancer diagnostic workflow," Tanja Brycker, Vice President of Strategic Development for Breast and Skeletal Health and Gynecological Solutions at Hologic, told the media. "As one of the global leaders in mammography and women's health, we are committed to enabling healthier lives every day around the world. By expanding global access to advanced breast imaging technologies for women, our international partnership with Bayer is a compelling example of this commitment."

▲Gerd Krueger

President of Bayer RadiologyGerd KruegerAdded to say"Breast cancer is the most common cancer in the world, affecting millions of women and their loved ones globally."Accurate and timely testing is crucial for improving patient outcomes and saving lives."We are pleased to partner with Hologic to provide our customers with comprehensive solutions and increase access to emerging breast imaging modalities, which can help improve diagnostic accuracy and offer another imaging option for many women who need it.”

# About Bayer

Bayer is a global enterprise with core competencies in the life sciences, specifically in healthcare and nutrition.Its productionProducts and services are designed to help humanity and the planet thrive by supporting efforts to address the significant challenges posed by global population growth and aging.Growth.

As a company with over 100 years of history in the field of radiology, Bayer is committed to providing innovative products and high-quality services to support efficient and optimized patient care.Bayer offers leading computed tomography (CT), X-ray and magneticMagnetic Resonance Imaging (MRI) Contrast AgentsProduct Portfolio,As well as devices, informatics solutions, and accessibility for precise managementMedical Imaging Platform for Applications (Including Applications Enabled by Artificial Intelligence (AI))。

Bayer's radiology products in 2022Generated nearly 2 billion euros in sales.Bayer aims to outpace the radiology market’s average annual growth rate of 5% by 2030, which is why the company is highly committed to research and development, including leveraging artificial intelligence and driving innovation in the field of medical imaging.

In fiscal 2022, the group had approximately 101,000 employees and sales of 50.7 billion euros.

# About Hologic, Inc.

Hologic, Inc. is a global medical technologyTechnological innovators, primarily dedicated to early detection and treatmentTherapyTo improve women's health and well-being.It created the world's first commercial 3D breast X-ray examination system to combat breast cancer;Taking a leadership role in cervical cancer, sexually transmitted infections, respiratory diseases, and COVID-19 testing;The company has also developed minimally invasive surgical techniques for uterine fibroids and abnormal uterine bleeding.

The company supports women through the Hologic Global Women’s Health Index and Project Health Equality. The Hologic Global Women’s Health Index provides a data-driven roadmap, backed by science, to improve women's well-being.

Editor｜Zhao Qing Reviewer｜Yi He Typesetter｜Miya